CN105705144A - Zinc-containing sleep-improving agent, non-rem sleep time-increasing agent, and sedative - Google Patents
Zinc-containing sleep-improving agent, non-rem sleep time-increasing agent, and sedative Download PDFInfo
- Publication number
- CN105705144A CN105705144A CN201480060928.7A CN201480060928A CN105705144A CN 105705144 A CN105705144 A CN 105705144A CN 201480060928 A CN201480060928 A CN 201480060928A CN 105705144 A CN105705144 A CN 105705144A
- Authority
- CN
- China
- Prior art keywords
- sleep
- fatty acid
- zinc
- improving agent
- acid ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The purpose of the present invention is to provide a sleep-improving agent by which a feeling of deep sleep is obtained, a non-REM sleep time-increasing agent, and a sedative. The sleep-improving agent of the present invention contains zinc, and sugars and/or sugar alcohol.
Description
Technical field
The present invention relates to a kind of sleep-improving agent, nonrapid eye movements,sleep time dose and tranquilizer。
Background technology
In modern society, there is the worried number about insomnia to increase year by year。As insomnia reason, it may be considered that various physiologic factors, psychological factor, recently, it is stated that the insomnia in increase trend main reason is that the insomnia caused by psychological causes。Example as reason, it is possible to enumerate the reduction etc. of the autonomic nerve integrated compensation power caused in pressure society by various troubles and worries。
Thus, in the society environment that mental pressure constantly increases, it is necessary to a kind of there is the sleeper effect of excellence, additionally there is the compositions of sedation effect。
Further, sleep has rapid-eye-movement sleep (REM sleep) and nonrapid eye movements,sleep。Known common sleep is combined by the rest period of brain and the rest period of nonrapid eye movements,sleep and health and rapid-eye-movement sleep (REM sleep) and is constituted, and healthy adult is repeated several times by this sleep on one, until wake up in the morning。Good sleep is the resting state and the nonrapid eye movements,sleep that concentrate on brain after just falling asleep, and its time is long。But, the many sleeps of the National People's Congress pouring out insomnia are shallow, in the mensuration of the sleep undertaken by brain wave, know shorter with the nonrapid eye movements,sleep time compared with the satisfied people that sleeps。
As the technology relevant with the sleep improvement feeling worried people because of this insomnia, the effect of natural component is widely known by the people。Cedrol as one of the fragrance component being contained in the coniferous tree such as Cupressus funebris, cypress, it is believed that total sleep time can be extended, shorten dropping asleep latency, improve Sleep efficiency (patent documentation 1)。
Prior art literature
Patent documentation
Patent documentation 1: No. 01/058435 pamphlet of International Publication publication
Summary of the invention
The technical task that invention to solve
As sleep improvement, do not require nothing more than and increase the length of one's sleep, but also the sense that requires to sleep soundly。Thinking sleep soundly sense be can pass through the increase of nonrapid eye movements,sleep time, the shortening of dropping asleep latency, calmness when sleeping such as reduction of midway awakening and obtain。At present, as sleep improvement effect, not yet obtain that there is the compositions increasing nonrapid eye movements,sleep chronergy。
The sleep soundly sleep-improving agent of sense, nonrapid eye movements,sleep time dose and tranquilizer can be obtained as it has been described above, expect to develop。
It is an object of the invention to provide and a kind of obtain the sleep soundly sleep-improving agent of sense, nonrapid eye movements,sleep time dose and tranquilizer。
For solving the means of technical task
That is, the present invention is as described below。
[1] a kind of sleep-improving agent, it contains zinc, saccharide and/or sugar alcohols。
[2] according to the sleep-improving agent described in [1], wherein, described saccharide is at least one of the group selecting free monosaccharide, polysaccharide and their carboxylate to constitute, and described sugar alcohols is sugar alcohol and/or its carboxylate。
[3] according to the sleep-improving agent described in [1] or [2], it contains at least one of zinc and the group selecting free inulin, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester to constitute。
[4] according to sleep-improving agent described in [3], wherein, polyglyceryl fatty acid ester is average degree of polymerization be more than 2 polyglycereol and the ester of fatty acid that carbon number is 8～18。
[5] according to sleep-improving agent described in [3] or [4], wherein, sucrose fatty acid ester is the ester of sucrose and fatty acid that carbon number is more than 12。
[6] according to the sleep-improving agent described in [3], it contains zinc and inulin。
[7] according to the sleep-improving agent described in [3], it contains zinc and oligosaccharide。
[8] according to the sleep-improving agent described in [3] or [4], it contains zinc and polyglyceryl fatty acid ester。
[9] according to the sleep-improving agent according to any one of [3]～[5], it contains zinc and sucrose fatty acid ester。
[10] according to the sleep-improving agent according to any one of [1]～[9], it is added into the form of yeast for zinc。
[11] a kind of nonrapid eye movements,sleep time dose, it contains at least one of zinc and the group selecting free inulin, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester to constitute。
[12] a kind of tranquilizer, it contains at least one of zinc and the group selecting free inulin, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester to constitute。
Invention effect
In accordance with the invention it is possible to provide a kind of to obtain the sleep soundly sleep-improving agent of sense, nonrapid eye movements,sleep time dose and tranquilizer。
Accompanying drawing explanation
Fig. 1 is the chart that the action number of times to embodiments of the invention 1～3, each test portion of comparative example 1,2 compares。
Fig. 2 is the chart that the sample to embodiments of the invention 1～3, each test portion of comparative example 1,2 is administered that latter 6 hours interior accumulation action amounts compare。
Fig. 3 is the chart that the action number of times to embodiments of the invention 4～7, each test portion of comparative example 3,4 compares。
Fig. 4 is the chart that the sample to embodiments of the invention 4～7, each test portion of comparative example 3,4 is administered that latter 6 hours interior accumulation action amounts compare。
Detailed description of the invention
It is defined below sleep-improving agent involved in the present invention, nonrapid eye movements,sleep time dose and tranquilizer。
Generally, sleep repetition rapid-eye-movement sleep (REM sleep) and nonrapid eye movements,sleep, deep sleep and nonrapid eye movements,sleep concentrate on the period of about 3 hours after sleep。One of sleep disorder is lost by the nonrapid eye movements,sleep of this degree of depth or shortens and cause, thus sleep quality reduces。Further, when insomnia, occurring that dropping asleep latency (until fall asleep time) is longer continually, midway awakening (in sleep, sleep shoals, and awakening), in this situation, the quality of same sleep can reduce。
If using sleep-improving agent involved in the present invention, nonrapid eye movements,sleep time dose or tranquilizer, then can increase the nonrapid eye movements,sleep time, and can obtain, by the shortening of dropping asleep latency, the reduction awakened and good awakening halfway, sense of sleeping soundly, awakening when getting up is also good, it is as a result, it is possible to improve the quality of sleep。
In the present invention, " sleep improvement " refer to sleep soundly sense higher, including the nonrapid eye movements,sleep time increase and sleep time calmness at least one。" calmness " in the present invention refers to calmness during sleep, including at least one in the shortening of dropping asleep latency, the reduction of midway awakening, good awakening。
In this manual, the term of " operation " is not merely independent operation, even if being situation about clearly cannot distinguish with other operations, if the intended purpose of operation can be realized, is then also contained in this term。
Further, in this manual, "～" represent the scope included by the numerical value being recorded in before and after it as minima and maximum。
It addition, when there is several material being equivalent to each composition in the composition, if being not particularly limited, then in this specification, the amount of each composition in compositions refers to the total amount of these several materials being present in compositions。
Hereinafter, the present invention will be described。
The sleep-improving agent of the present invention contains zinc, saccharide and/or sugar alcohols。Described saccharide is preferably selected from least one of the group being made up of monosaccharide, polysaccharide and their carboxylate。Described sugar alcohols is that saccharide carries out reducing the material obtained, it is preferred to sugar alcohol and/or its carboxylate。In this manual, saccharide, sugar alcohols carboxylate refer to that at least one of hydrogen-based that saccharide, sugar alcohols have is esterified。
< zinc >
The sleep-improving agent of the present invention includes zinc。Zinc can be present in sleep-improving agent as monomer, it is also possible to exists with the state combined with protein etc., it is also possible to coordinate as zinc gluconate, and exists with ionic condition, it is also possible to is added to the form (Zn-contained yeast) in yeast。
Zn-contained yeast refers to culture yeasts in the culture medium adding zinc with high concentration, thus by zinc-iron alloy solution to endobacillary yeast。These Zn-contained yeast can pass through in the culture medium adding zinc culture yeasts and after being collecting bacteria, and obtains through concentration, sterilization, the operation such as dry。Further, it is possible to use commercially available Zn-contained yeast。As commercially available yeast, it is possible to enumerate Saccharomyces (yeast) genus, Mycotorula (candida mycoderma) genus, Torulopsis (torula) genus etc., bakery yeast, beer yeast, wine yeast, saccharomyces sake, brewer yeast, taste increase the edible yeasts etc. such as oil yeast。
This Zn-contained yeast is added in the thalline of yeast due to zinc, will not feel that metallic taste just can be absorbed, it is thus preferred to。It addition, Zn-contained yeast adds mineral in yeast body, so that mineral and protein bound become organism, when being therefore applied to the mammals including people, compared with inorganic zinc, improve internal absorption。
As long as improving the amount of effect as to the consumption that makes of the mammiferous zinc including people for conducing to sleep, specifically, as zinc amount, every day is preferably 1mg～300mg, more preferably 2mg～100mg, more preferably 3mg～50mg。
Further, when coordinating zinc with the form of Zn-contained yeast, as to the mammiferous consumption that makes including people, the Functionality, quality and appealing design of the Zn-contained yeast of every day elects 5mg～6000mg as, more preferably 20mg～2000mg, more preferably 25mg～300mg。
The sleep-improving agent of the present invention includes the zinc of described above, saccharide and/or sugar alcohols。
As saccharide, can enumerate general structure is aldose, ketose, pyranose, furanose, for instance can enumerate the monosaccharides such as glyceraldehyde, erythrose, threose, ribose, lyxose, xylose, arabinose, allose, talose, gulose, glucose, altrose, mannose, galactose, idose, dihydroxy acetone, Erythrulose, xylulose, ribulose, psicose, levulose, sorbose, Tagatose；The polysaccharides such as oligosaccharide, inulin, dextrin, sucrose, lactose, maltose, trehalose, maltotriose, acarbose；And the carboxylate of the saccharide such as sucrose fatty acid ester, sorbitan fatty acid esters (monosaccharide, polysaccharide)。
As sugar alcohols, it is possible to enumerate the sugar alcohols such as glycerol, erythritol or Sorbitol, xylitol, sucrose；The carboxylate of the sugar alcohol such as polyglyceryl fatty acid ester, methyl glycol fatty acid ester。
Such as, the sleep-improving agent of the present invention includes the zinc of described above and is selected from least one of inulin, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester。
These compositions can be used alone or two or more kinds may be used。
In the sleep-improving agent of the present invention, to include the mammiferous saccharide of people and/or sugar alcohols make consumption (to include people the mammiferous at least one being selected from inulin, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester make consumption) as long as improving the amount of effect for conducing to sleep, specifically, every day is preferably 1mg～1000mg, it is more preferably 2mg～300mg, more preferably 3mg～100mg。
In the sleep-improving agent of the present invention, the mass ratio (mass ratio of at least one that such as zinc and the free inulin of choosing, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester are constituted) of zinc and saccharide and/or sugar alcohols, viewpoint from sleep improvement effect, it is preferably 1:100～100:1, more preferably 1:80～80:1。
< inulin >
The one of the saccharide (especially polysaccharide) that can use in the sleep-improving agent of the present invention and inulin, refer to the fructose polymer that mean molecule quantity is 3000～8000 or the fructose oligomer at end with 1 glucose。Known inulin is widely present in nature, is contained in Herba Cichorii, Jerusalem artichoke, Dahlia Pinnata Cav., Bulbus Allii, Folium Allii tuberosi, Bulbus Allii Cepae etc. more。Inulin as the present invention, it is possible to use the root separation hot water extraction from Herba Cichorii, Jerusalem artichoke, Dahlia Pinnata Cav., Bulbus Allii, Folium Allii tuberosi, Bulbus Allii Cepae etc., this aqueous solution is concentrated, and the inulin that powdered is commercially available by spray drying。Such as, the DownyNeo (OfuratiCo. system) that can enumerate the Frutafit (SENSLtd. system) extracted from Herba Cichorii root, extracts from Herba Cichorii root, come from the reagent (WakoPureChemicalIndustries, Ltd. system, Sigma-AldrichCo.LLC. system) of Dahlia Pinnata Cav. root, Herba Cichorii root extracts reagent (Sigma-AldrichCo.LLC. system) etc.。
As long as the consumption that makes of the mammiferous inulin including people is improved the amount of effect in order to conduce to sleep, specifically, every day is preferably 1mg～1000mg, more preferably 2mg～300mg, more preferably 3mg～100mg。
As an example of the sleep-improving agent of the present invention, containing zinc and inulin。The mass ratio of zinc and inulin, from the viewpoint of sleep improvement effect, it is preferred to 1:100～100:1, more preferably 1:75～75:1。
< oligosaccharide >
The one of the saccharide (especially polysaccharide) that can use in the sleep-improving agent of the present invention and oligosaccharide, be widely present in nature by known, be contained in Bulbus Allii Cepae, Brassica oleracea L.var.capitata L., Rhizoma Solani tuber osi, Bulbus Allii, Semen Maydis, burdock, Radix Betae etc. more。Oligosaccharide as the present invention, it is possible to use and separate hot water extraction from Bulbus Allii Cepae, Brassica oleracea L.var.capitata L., Rhizoma Solani tuber osi, Bulbus Allii, Semen Maydis, burdock, Radix Betae etc., this aqueous solution is concentrated, and the oligosaccharide that powdered is commercially available by spray drying。Further, it is possible to use the oligosaccharide polysaccharide of plant being carried out enzyme decomposition and obtain, and utilize the oligosaccharide of the fermented method synthesis of microorganism。Such as Oligotose (MitsubishiChemicalCorporation. system), DekishiparuK-100 (EnsuikoSugarRefiningCo., Ltd. system)。
As long as the consumption that makes of the mammiferous oligosaccharide including people is improved the amount of effect in order to conduce to sleep, specifically, every day is preferably 10mg～10g, more preferably 30mg～3g, more preferably 50mg～1g。
As an example of the sleep-improving agent of the present invention, containing zinc and oligosaccharide。The mass ratio of zinc and oligosaccharide, from the viewpoint of sleep improvement effect, it is preferred to 1:100～100:1, more preferably 1:75～75:1。
< polyglyceryl fatty acid ester >
One and polyglyceryl fatty acid ester as the sugar alcohols (especially the carboxylate of sugar alcohol) that can use in the sleep-improving agent of the present invention, average degree of polymerization can be enumerated and be preferably more than 2, be more preferably 6～15, more preferably 8～10 polyglycereol and the ester of fatty acid that carbon number is 8～18。It is the fatty acid of 8～18 as carbon number, for instance sad, capric acid, lauric acid, myristic acid, Palmic acid, stearic acid, oleic acid and linoleic ester can be enumerated。
As polyglyceryl fatty acid ester, it is possible to enumerate six glycerol glyceryl monooleates, six glyceryl monostearates, six glycerol monopalmitate, six monomyristins, six glyceryl monolaurates, SY-Glyster MO 750, SY-Glyster MSW 750, ten glycerol monopalmitate, ten monomyristins, DECAGLYCERYL MONOLAURATE etc.。Wherein, it is preferable that SY-Glyster MO 750 (HLB=12), SY-Glyster MSW 750 (HLB=12), ten glycerol monopalmitate (HLB=13), ten monomyristins (HLB=14), DECAGLYCERYL MONOLAURATE (HLB=16)。
These polyglyceryl fatty acid esters can be used alone or as a mixture。
Polyglyceryl fatty acid ester can use commercially available product。As commercially available product, for instance NikkoChemicalsCo., Ltd. system can be enumerated, NIKKOLDGMS, NIKKOLDGMO-CV, NIKKOLDGMO-90V, NIKKOLDGDO, NIKKOLDGMIS, NIKKOLDGTIS, NIKKOLTetraglyn1-SV, NIKKOLTetraglyn1-O, NIKKOLTetraglyn3-S, NIKKOLTetraglyn5-S, NIKKOLTetraglyn5-O, NIKKOLHexaglyn1-L, NIKKOLHexaglyn1-M, NIKKOLHexaglyn1-SV, NIKKOLHexaglyn1-O, NIKKOLHexaglyn3-S, NIKKOLHexaglyn4-B, NIKKOLHexaglyn5-S, NIKKOLHexaglyn5-O, NIKKOLHexaglynPR-15, NIKKOLDecaglyn1-L, NIKKOLDecaglyn1-M, NIKKOLDecaglyn1-SV, NIKKOLDecaglyn1-50SV, NIKKOLDecaglyn1-ISV, NIKKOLDecaglyn1-O, NIKKOLDecaglyn1-OV, NIKKOLDecaglyn1-LN, NIKKOLDecaglyn2-SV, NIKKOLDecaglyn2-ISV, NIKKOLDecaglyn3-SV, NIKKOLDecaglyn3-OV, NIKKOLDecaglyn5-SV, NIKKOLDecaglyn5-HS, NIKKOLDecaglyn5-IS, NIKKOLDecaglyn5-OV, NIKKOLDecaglyn5-O-R, NIKKOLDecaglyn7-S, NIKKOLDecaglyn7-O, NIKKOLDecaglyn10-SV, NIKKOLDecaglyn10-IS, NIKKOLDecaglyn10-OV, NIKKOLDecaglyn10-MAC, NIKKOLDecaglynPR-20, Mitsubishi-KagakuFoodsCorporation. RYOTO polyglycerin ester L-7D processed, L-10D, M-10D, P-8D, SWA-10D, SWA-15D, SWA-20D, S-24D, S-28D, O-15D, O-50D, B-70D, B-100D, ER-60D, LOP-120DP, DS13W, DS3, HS11, HS9, TS4, TS2, DL15, DO13, TaiyoKagakuCo., Ltd. SunsoftQ-17UL, SunsoftQ-14S, SunsoftA-141C, RikenVitaminCo., Ltd. POEMDO-100, POEMJ-0021 etc.。
As long as the consumption that makes of the mammiferous polyglyceryl fatty acid ester including people is improved the amount of effect in order to conduce to sleep, specifically, every day is preferably 1mg～1000mg, more preferably 2mg～300mg, more preferably 3mg～100mg。
One example of the sleep-improving agent of the present invention, containing zinc and polyglyceryl fatty acid ester。Zinc in the sleep-improving agent of the present invention and the mass ratio of polyglyceryl fatty acid ester, from the viewpoint of sleep improvement effect, it is preferred to 1:20～20:1, more preferably 1:10～10:1。
< sucrose fatty acid ester >
One and sucrose fatty acid ester as the saccharide (especially, the carboxylate of polysaccharide) that can use in the sleep-improving agent of the present invention, it is possible to enumerate sucrose and preferred carbon number is more than 12, is more preferably the ester of the fatty acid of 12～20。
As sucrose fatty acid ester, sucrose dioleate, sucrose distearate, sucrose dipalmitate, sucrose two myristinate, sucrose dilaurate, sucrose-mono-oleate, sucrose monostearate, sucrose palmitic acid ester, sucrose monomyristate, sucrose monolaurate etc. can be enumerated, wherein, it is preferably sucrose-mono-oleate, sucrose monostearate, sucrose palmitic acid ester, sucrose monomyristate, sucrose monolaurate, especially, more preferably sucrose monolaurate, sucrose-mono-oleate。
In the present invention, these sucrose fatty acid ester can be used alone or as a mixture。
Sucrose fatty acid ester can use commercially available product。As commercially available product, such as can enumerate Mitsubishi-KagakuFoodsCorporation. RYOTO sugar ester S-070, S-170, S-270, S-370, S-370F, S-570, S-770, S-970, S-1170, S-1170F, S-1570, S-1670, P-070, P-170, P-1570, P-1670, M-1695, O-170, O-1570, OWA-1570, L-195, L-595, L-1695, LWA-1570, B-370, B-370F, ER-190, ER-290, POS-135, DKSCo.Ltd. DK ester SS processed, F160, F140, F110, F90, F70, F50, F-A50, F-20W, F-10, F-A10E, CosmeticslikeB-30, S-10, S-50, S-70, S-110, S-160, S-190, SA-10, SA-50, P-10, P-160, M-160, L-10, L-50, L-160, L-150A, L-160A, R-10, R-20, O-10, O-150 etc.。
In the sleep-improving agent of the present invention, as long as the consumption that makes of the mammiferous sucrose fatty acid ester including people is improved the amount of effect in order to conduce to sleep, specifically, every day is preferably 1mg～1000mg, it is more preferably 2mg～300mg, more preferably 3mg～100mg。
One example of the sleep-improving agent of the present invention, containing zinc and sucrose fatty acid ester。Zinc in the sleep-improving agent of the present invention and the mass ratio of sucrose fatty acid ester, from the viewpoint of sleep improvement effect, it is preferred to 1:20～20:1, more preferably 1:10～10:1。
The sleep-improving agent of the present invention is preferably applied in food and pharmaceuticals。At this, as food, it is possible to enumerate the processed foods etc. such as beverage, cake, or rice dumpling, sandwich, soup, cup face, braised meal, and, as pharmaceuticals, it is possible to enumerate nutritious drink, tonic invigorator etc., but it is not limited to this。
In the sleep-improving agent of the present invention, additionally it is possible to add and can make an addition to the arbitrary composition in food or pharmaceuticals。
As the carrier being preferably used when making solution shape, it is possible to enumerate the aqueous mediums such as water。As the adding ingredient being preferably used when making solid shape, it is possible to use as crystalline cellulose, magnesium stearate excipient, as corn starch, alginic acid swelling agent。
It addition, as any composition that can make an addition in food or pharmaceuticals, it is possible to use agent of low hygroscopicity raw material, hygroscopic agent。And, it is possible to use the compound (such as Kaolin, Talcum etc.) required when being shaped to powder, shape-fixing agent or liquor。
There is no particular restriction for the administering mode of the sleep-improving agent of the present invention, it is possible to is administered in the way of being administered orally or be parenteral。As for oral use dose of form, it is possible to enumerate the such as solid such as tablet, intraorally rapidly disintegrating sheet, capsule preparations, granule, particulate and take the liquid such as mode, syrup and suspension and take form。As parenteral dose of form, it is possible to enumerate injection, eye drop, attach agent, the form such as ointment, suppository。Administering mode as the sleep-improving agent of the present invention, it is preferred to administering mode for oral use, from the viewpoint easily taken, it is preferred to take mode by the solid of capsule preparations。
When the sleep-improving agent of the present invention is made capsule preparations, it is possible to enumerate the modes such as hard capsule, soft capsule, microcapsule, Sealmess capsule。The overlay film of capsule preferably one or more by pigskin gelatin, Swine bone gelatin, isinglass or natural hydrophilic polymer are constituted。These capsule overlay films can be prepared by known customary way。At this, it is made up of pigskin gelatin, Swine bone gelatin, isinglass or natural hydrophilic polymer, refer to that relative to the total content of the pigskin gelatin of capsule overlay film gross mass, Swine bone gelatin, isinglass or natural hydrophilic polymer be more than 30 mass %, it is preferably more than 40 mass %, it is more preferably more than 50 mass %, it is particularly preferred that be more than 60 mass %。As long as it addition, do not damage the effect of the present invention, capsule overlay film can also contain the other materials such as cattle hide gelatin。
Natural hydrophilic polymer be with natural animals and plants etc. for source by the hydrophilic polymer purifying or being synthesized into or its processable polymer, can exemplify selected from alginic acid or its salt, agaropectin, guar gum, locust bean gum, tara gum, gum ghatti, Mahogany glue (khayagrandifoliagum), Tragacanth, POLY-karaya, pectin, arabic gum, xanthan gum, gellan gum, starch, Konjaku plucosidopolyose, galactomannan, funoran, acetan glue, Weilan gum, Fructus rhamni (Rhamnus davurica Pall.) glue, Furcellaran, succinoglycan, scleroglycan (scleroglycan), Schizophyllan (schizopyllan), tamarind gum, curdlan, carrageenin, at least one etc. in pulullan polysaccharide or glucosan。These can be used in combination of two or more, it is also possible to combines with above-mentioned pigskin gelatin etc.。These hydrophilic polymeies can also be the material of processing natural goods。Wherein, it is particularly preferred that pulullan polysaccharide, carrageenin, glucosan, it is particularly preferred that carrageenin。
Pigskin gelatin, Swine bone gelatin, isinglass refer to the protein that the protein obtained with Corii Sus domestica, Os Sus domestica, fish carries out warm water extraction for raw material。The pigskin gelatin of the present invention, Swine bone gelatin, isinglass can purify as follows, namely after such as with acid or alkali Corii Sus domestica, Os Sus domestica, Perciformes, morrhua, tuna, bathypelagic fish etc. being processed, water heats and extracts, and purify through ion-exchange treatment operation。
Pigskin gelatin, Swine bone gelatin, isinglass or natural hydrophilic polymer can pass through ferment treatment etc. and carry out degraded, mean molecule quantity can be properly carried out selecting, and is generally 1～5,000,000, it is preferred to 10,000～2,500,000, it is more preferably 10,000～1,000,000, more preferably 10,000～about 500,000。
It is used in the capsule overlay film in capsule preparations, does not contain only and above state the raw material for source such as specific animals and plants, it is also possible to containing oils and fats, polyhydric alcohol, surfactant, antioxidant, colouring matter, spice etc.。As oils and fats, such as can enumerate Radix Oenotherae erythrosepalae oil, soybean oil, safflower oil, olive oil, germ oil, Oleum Brassicae campestris, Oleum helianthi, Oleum Arachidis hypogaeae semen, continuous seed oil, Testa oryzae oil, cocoa wet goods natural oil or their fixed oil, glyceride (the glyceride of fatty acid, two glyceride, triglyceride etc.) etc., as polyhydric alcohol, Polyethylene Glycol can be enumerated, propylene glycol, glycerol, Sorbitol etc., as surfactant, the nonionic surfactant such as sorbitan fatty acid esters or polyglyceryl fatty acid ester etc. can be enumerated, as coloring agent (pigment), carotenoids prime system color element can be enumerated, cyanine prime system color element, cacao color, anthraquinone system color element, caramel color etc.。Wherein, from the viewpoint of the stabilisation of capsule preparations can be improved further, it is preferable that capsule overlay film is added oils and fats, polyhydric alcohol, surfactant, natural pigment。
The sleep-improving agent of the present invention is obtained in that good sense of sleeping soundly by taking。As Time of Administration, it is preferable that take before bedtime, more preferably within 0.5～6 hour, take before bedtime, it is preferred that took before 1～3 hour before bedtime。
The sleep-improving agent of the present invention is different according to the age of user, body weight, instructions of taking etc., and 1 time dose is 0.001mg/kg/ days～about 10000mg/kg/ days, it is preferred to 2.5mg/kg/ days～about 20mg/kg/ days。
The nonrapid eye movements,sleep time dose of the present invention contains zinc and at least one selected from inulin, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester。Nonrapid eye movements,sleep time dose in the present invention can increase nonrapid eye movements,sleep amount by taking。As Time of Administration, it is preferable that take before bedtime, more preferably within 0.5～6 hour, take before bedtime, it is preferred that took before 1～3 hour。
The nonrapid eye movements,sleep time dose of the present invention is different according to the age of user, body weight, instructions of taking etc., and 1 time dose is 0.001mg/kg/ days～about 10000mg/kg/ days, it is preferred to 2.5mg/kg/ days～about 20mg/kg/ days。
The other business of the nonrapid eye movements,sleep time dose of the present invention, it is possible to suitable in the item illustrated sleep-improving agent involved in the present invention。
The tranquilizer of the present invention contains zinc and at least one selected from inulin, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester。Tranquilizer refers to the mammiferous psychosedation making to include people in sleep such that it is able to obtain relaxation effects such as relaxing tense situation, ease off the pressure。
If taking the tranquilizer of the present invention before bedtime, then successfully being fallen asleep by relaxation effect, shortening or the effect of the reduction of midway awakening, awakening good when getting up of dropping asleep latency can be obtained。Accordingly, as Time of Administration, it is preferable that take before bedtime。More preferably within 0.5 hour～6 hours, take before bedtime, it is preferred that take before 1 hour～3 hours。
The tranquilizer of the present invention is different according to the age of user, body weight, instructions of taking etc., and 1 time dose is 0.001mg/kg/ days～about 10000mg/kg/ days, it is preferred to 2.5mg/kg/ days～about 20mg/kg/ days。
Ataractic other business about the present invention, it is possible to suitable in the item illustrated sleep-improving agent involved in the present invention。
Embodiment
Below, it is shown that the present invention is specifically described by embodiment, but the present invention by the restriction of following embodiment。
[embodiment 1～3, comparative example 1,2]
1. method
I () uses animal
C57BL/6 mice (male, birth after 8 weeks, body weight 22～26g) is bought from SLC。
(ii) method for breeding
5～6 above-mentioned mices respectively put into by each cage of multiple propylene systems in the chamber being arranged at constant temperature (22 ± 2 DEG C), constant humidity (50 ± 2%), carry out managing (collective raising mice to each mice。)。With every the light and shade cycle (morning 7 point of 12 hours；The start time in bright cycle), make mice freely absorb mice solid type feedstuff (feedstuff title: LaboMRStock) and water。
(iii) mensuration of action amount
Then, be arranged at the constant temperature (22 ± 2 DEG C) different from above-mentioned chamber, constant humidity (50 ± 2%) chamber (following, sometimes referred to as record chamber。) in multiple each propylene cage in, the mice after 1 collective raising of transfer respectively, at above-mentioned rearing conditions (with every the light and shade cycle (morning 7 point of 12 hours；The start time in bright cycle), it is possible to the freely picked-up mice condition of solid type feedstuff and water) under, make them adapt to 3 days (individual breeding mices。)。Confirm the action amount (following give sample the action amount of first 24 hours) of the mice of the 3rd day in record chamber。
The sensor (BiotexJapanCorporation. system) that the infrared ray discharged from animal is detected and software Biotex16CHActMonitorBAI2216 (BiotexJapanCorporation. system) is used to have recorded action amount。
The sensing range of this sensor extends with the irradiating angle of 90 degree, and this scope is divided into 64 regions of 8 × 8, and the number of times that animal crosses this region is calculated as action amount。
(iv) sample preparation, administration
As embodiment 1, beer yeast zinc (containing zinc 3 mass %) and inulin (FujiFF:FujinihonseitoCorporation. system) will be dissolved in the sample of pure water 10ml with 11:20 mixture (sleep-improving agent) 775mg carrying out coordinating, use probe to mice (n=7) oral administration after individual breeding。Dosage has adjusted in the way of the mice of every 1kg gives the sample of 10g。
As embodiment 2, will beer yeast zinc (containing zinc 3 mass %) and lauric acid Natrulon H-10 (NIKKOLDecaglyn1-L:NikkoChemicalsCo., Ltd. system) sample of pure water 10ml it is dissolved in the 1:2 mixture 375mg carrying out coordinating, use probe to mice (n=7) oral administration after individual breeding。Sample dosage is identical with embodiment 1。
As embodiment 3, beer yeast zinc (containing zinc 3 mass %) and Surfhope SE Cosme C 1216 (RYOTO sugar ester L-1695:Mitsubishi-KagakuFoodsCorporation. system) will be dissolved in the sample of pure water 10ml with the 1:2 mixture 375mg carrying out coordinating, use probe to mice (n=7) oral administration after individual breeding。Sample dosage is identical with embodiment 1。
In comparative example 1, by the pure water (sample) of the dosage (10g/kg) identical with embodiment 1, use probe to mice (n=7) oral administration after individual breeding。
In comparative example 2, beer yeast zinc (containing zinc 3 mass %) 275mg will be dissolved in the sample of pure water 10ml, use probe mice (n=7) oral administration to individual breeding。Sample dosage is identical with embodiment 1。
In point in afternoon 7 (start time of dark phase), the mice in the record chamber having confirmed that after giving the sample action amount of first 24 hours is carried out sample administration。
The record of (v) action amount
After oral administration, in order to mice is applied pressure, mice is transferred to other propylene cages in record chamber, in record chamber, at above-mentioned rearing conditions (with every the light and shade cycle (morning 7 point of 12 hours；The start time in bright cycle), be free to picked-up mice solid type feedstuff and the condition of water) under raise, measure 12 hours interior action amounts (have recorded the number of times every 1 hour), and calculate from oral administration to 6 hours every the accumulation action amount of 1 hour。It addition, the average time of every 1 mice of row momentum representation。
Then, under above-mentioned rearing conditions, continue to raise in record chamber, and carried out the observation of 24 hours。
2. result
Sample is administered in latter 12 hours and is administered latter 6 hours interior accumulation action amounts every the number of times of the action amount of 1 hour and sample, respectively shown in Fig. 1, Fig. 2。
In an embodiment, compared with each comparative example, in sample dosage 10g/kg, action amount substantially reduces。
[embodiment 4～7, comparative example 3,4]
1 mice (same mice) for individual breeding in the same manner as in Example 1, undertaken being administered (namely by following method by the sample prepared by following method, same mice is implemented following embodiment and comparative example successively), in addition, action amount is determined in the same manner as example 1。To the mice implemented after an embodiment or comparative example, before implementing next embodiment or comparative example, transfer to other propylene cages being arranged in record chamber, and at above-mentioned rearing conditions (under the light and shade cycle of the 12 hours (morning 7 point；The start time in bright cycle), it is possible to freely picked-up the mice condition of solid type feedstuff and water) under raised 3 days。
(i) sample preparation, administration
As embodiment 4, beer yeast zinc (containing zinc 3 mass %) and oligosaccharide (Oligotose:Mitsubishi-KagakuFoodsCorporation. system) will be dissolved in the sample of pure water 10ml with 11:20 mixture (sleep-improving agent) 775mg carrying out coordinating, use probe to mice (n=1) oral administration in record chamber。Dosage has adjusted in the way of every 1kg mice gives 10g sample。
As embodiment 5, beer yeast zinc (containing zinc 3 mass %) and sucrose oleate (RYOTO sugar ester O-1570:Mitsubishi-KagakuFoodsCorporation. system) will be dissolved in the sample of pure water 10ml with the 1:2 mixture 375mg carrying out coordinating, use probe to mice (n=1) oral administration in record chamber。Sample dosage is identical with embodiment 4。
As embodiment 6, beer yeast zinc (containing zinc 3 mass %) and sucrose stearate (RYOTO sugar ester S-1670:Mitsubishi-KagakuFoodsCorporation. system) will be dissolved in the sample of pure water 10ml with the 1:2 mixture 375mg carrying out coordinating, use probe to mice (n=1) oral administration in record chamber。Sample dosage is identical with embodiment 4。
As embodiment 7, beer yeast zinc (containing zinc 3 mass %) and Sucrose myristate (RYOTO sugar ester M-1695:Mitsubishi-KagakuFoodsCorporation. system) will be dissolved in the sample of pure water 10ml with the 1:2 mixture 375mg carrying out coordinating, use probe to mice (n=1) oral administration in record chamber。Sample dosage is identical with embodiment 4。
In comparative example 3, by the pure water (sample) of the dosage (10g/kg) identical with embodiment 4, use probe to mice (n=1) oral administration in record chamber。
In comparative example 4, beer yeast zinc (containing zinc 3 mass %) 275mg will be dissolved in the sample of pure water 10ml, and use probe to mice (n=1) oral administration in record chamber。Sample dosage is identical with embodiment 4。
2. result
Sample is administered in latter 12 hours and is administered latter 6 hours interior accumulation action amounts respectively shown in Fig. 3, Fig. 4 every the number of times of the action amount of 1 hour and sample。
In an embodiment, compared with each comparative example, in sample dosage 10g/kg, action amount substantially reduces。
[embodiment 8, embodiment 9, comparative example 5]
1. method
I () uses animal
C57BL/6 mice (male, birth after 12 weeks, body weight 24～27g) is bought from SLC。
(ii) method for breeding
In multiple each propylene cage in the chamber being arranged at constant temperature (22 ± 2 DEG C), constant humidity (50 ± 2%), under the state respectively putting into 5～6 above-mentioned mices, carry out managing (by mice collective raising to each mice。)。With every the light and shade cycle (8 a.m. of 12 hours；The start time in bright cycle), make mice freely absorb mice solid type feedstuff (feedstuff title: LaboMRStock) and water。
(iii) brain wave, the treatment operation of myoelectric potential measuring electrode and the connection with determinator
Then, mice is implemented the treatment operation of brain wave, myoelectric potential measuring electrode, be arranged at the constant temperature (22 ± 2 DEG C) different from above-mentioned chamber, constant humidity (50 ± 2%) chamber (following, sometimes referred to as recovery chamber。) in multiple each propylene cage in, 1 postoperative mice of transfer respectively, at above-mentioned rearing conditions (with every the light and shade cycle (8 a.m. of 12 hours；The start time in bright cycle), it is possible to the freely picked-up mice condition of solid type feedstuff and water) under, raise 10 days (by mice individual breeding。)。Then, be arranged at the constant temperature (22 ± 2 DEG C) different from above-mentioned recovery chamber, constant humidity (50 ± 2%) chamber (following, sometimes referred to as record chamber。) in multiple each propylene cage in, respectively transfer 1 individual breeding after mice, and on electrode connect measure cable, at above-mentioned rearing conditions (every the light and shade cycle (8 a.m. of 12 hours；The start time in bright cycle), it is possible to the freely picked-up mice condition of solid type feedstuff and water) under, make mice adapt to 4 days。
(iv) sample preparation, administration
As embodiment 8, the mixture (sleep-improving agent) of beer yeast zinc (containing zinc 3 mass %) 275mg and inulin (FujiFF:FujinihonseitoCorporation. system) 100mg will be dissolved in the sample of pure water 10ml, use probe to mice (n=7) oral administration after individual breeding。Dosage has adjusted in the way of every 1kg mice gives 10g sample。
As embodiment 9, the mixture 375mg of 100mg will be coordinated to be dissolved in the sample of pure water 10ml beer yeast zinc (containing zinc 3 mass %) 275mg and sucrose stearate (RYOTO sugar ester S-1670:Mitsubishi-KagakuFoodsCorporation. system), use probe to mice (n=7) oral administration after individual breeding。Dosage has adjusted in the way of every 1kg mice gives 10g sample。
In comparative example 5, use probe by pure water mice (n=7) oral administration to individual breeding。Sample dosage is identical with embodiment 8。
In point in afternoon 8 (start time of dark phase), the mice after 4 days at record chamber endoadaptation is carried out sample administration。
(v) brain wave, the record of myoelectric potential and analysis
Brain wave and myoelectric potential are then after amplification (brain wave: 0.5-30Hz, myoelectric potential: 20-200Hz), with the sample rate digitized of 128Hz and carried out record。
EEG software " SleepSign " (KISSEICOMTECCO., LTD. system) is used to analyze。Specifically, using the data of 10 seconds as 1 period, by the frequency content of brain wave and myoelectric potential and waveform, it is any one in " awakening ", " nonrapid eye movements,sleep ", " rapid-eye-movement sleep (REM sleep) " by day part automatic decision。
Sample is administered latter 4 hours interior brain wave data analyzed, calculates the time of " awakening ", " nonrapid eye movements,sleep ", " rapid-eye-movement sleep (REM sleep) " of every 1 hour。Then, under above-mentioned rearing conditions, continue the raising in record chamber, and carried out the observation of 24 hours。
2. result
Sample is administered latter 4 hours interior nonrapid eye movements,sleep time and the awakening time illustrates in Table 1。It addition, the average time of every 1 mice of each time representation。
Finding in an embodiment, compared with comparative example, the effect extending the nonrapid eye movements,sleep time in dosage 10g/kg is notable。
[table 1]
| The nonrapid eye movements,sleep time | The awakening time | |
| Embodiment 8 | 60 | 179 |
| Embodiment 9 | 99 | 140 |
| Comparative example 5 | 39 | 200 |
In accordance with the invention it is possible to obtain excellent sleep improvement effect, enable in particular to obtain the effect increasing the nonrapid eye movements,sleep time。And, it is also possible to obtain the shortening of dropping asleep latency, the reduction of midway awakening, sedation effect and relaxation effect, and be obtained in that satisfied sense of sleeping soundly when getting up。
Claims (12)
1. a sleep-improving agent, it contains:
Zinc；And
Saccharide and/or sugar alcohols。
2. sleep-improving agent according to claim 1, wherein,
Described saccharide is at least one in the group selecting free monosaccharide, polysaccharide and their carboxylate to constitute, and described sugar alcohols is sugar alcohol and/or its carboxylate。
3. sleep-improving agent according to claim 1 and 2, it contains:
Zinc；And
Select at least one in the group of free inulin, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester composition。
4. sleep-improving agent according to claim 3, wherein,
Described polyglyceryl fatty acid ester is average degree of polymerization be more than 2 the ester of the fatty acid that polyglycereol and carbon number are 8～18。
5. the sleep-improving agent according to claim 3 or 4, wherein,
Described sucrose fatty acid ester is the ester of sucrose and the fatty acid that carbon number is more than 12。
6. sleep-improving agent according to claim 3, it contains zinc and inulin。
7. sleep-improving agent according to claim 3, it contains zinc and oligosaccharide。
8. the sleep-improving agent according to claim 3 or 4, it contains zinc and described polyglyceryl fatty acid ester。
9. the sleep-improving agent according to any one of claim 3 to 5, it contains zinc and described sucrose fatty acid ester。
10. sleep-improving agent according to any one of claim 1 to 9, wherein, zinc is the form being added in yeast。
11. a nonrapid eye movements,sleep time dose, it contains:
Zinc；And
Select at least one in the group of free inulin, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester composition。
12. a tranquilizer, it contains:
Zinc；And
Select at least one in the group of free inulin, oligosaccharide, polyglyceryl fatty acid ester and sucrose fatty acid ester composition。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013-271892 | 2013-12-27 | ||
| JP2013271892 | 2013-12-27 | ||
| PCT/JP2014/084448 WO2015099102A1 (en) | 2013-12-27 | 2014-12-26 | Zinc-containing sleep-improving agent, non-rem sleep time-increasing agent, and sedative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105705144A true CN105705144A (en) | 2016-06-22 |
Family
ID=53478942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480060928.7A Pending CN105705144A (en) | 2013-12-27 | 2014-12-26 | Zinc-containing sleep-improving agent, non-rem sleep time-increasing agent, and sedative |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPWO2015099102A1 (en) |
| CN (1) | CN105705144A (en) |
| WO (1) | WO2015099102A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI760507B (en) * | 2017-06-14 | 2022-04-11 | 日商朝日飲料股份有限公司 | Non-carbonated liquid food and drink containing microbial cells, and method for improving the dispersibility of sediment or aggregate of microbial cell powder in food and drink |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210352925A1 (en) * | 2019-02-04 | 2021-11-18 | N.V. Nutricia | Fermented formula with non digestible oligosaccharides for sleep improvement |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009261361A (en) * | 2008-04-28 | 2009-11-12 | Sanei Gen Ffi Inc | Thick liquid food containing vegetable protein |
| JP2012036112A (en) * | 2010-08-05 | 2012-02-23 | Sankyo:Kk | Method for manufacturing product for improving bioavailability, and the product |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0951842B1 (en) * | 1999-01-20 | 2002-12-04 | N.V. Nutricia | Infant formula |
| JP2004149471A (en) * | 2002-10-31 | 2004-05-27 | Shiratori Pharmaceutical Co Ltd | Hypoglycemic agent |
| JP2007236201A (en) * | 2004-03-02 | 2007-09-20 | Taiyo Kagaku Co Ltd | Mineral-enriching composition |
| JP2006160697A (en) * | 2004-12-10 | 2006-06-22 | Kao Corp | Sleep-related health ameliorative agent |
| JP5527986B2 (en) * | 2008-02-19 | 2014-06-25 | 株式会社アーネストメディスン | Pharmaceutical composition |
| JP2011062164A (en) * | 2009-09-18 | 2011-03-31 | Yumie Osada | Zinc-containing pasta |
| US20130273176A1 (en) * | 2010-12-07 | 2013-10-17 | Nestec Sa | Methods and compositions useful for promoting sleep in animals |
| JPWO2014054651A1 (en) * | 2012-10-03 | 2016-08-25 | 富士フイルム株式会社 | Sleep improving agent, non-REM sleep time increasing agent and sedative |
| JP2014172892A (en) * | 2013-03-12 | 2014-09-22 | Fujifilm Corp | Sleep improvement agent, non-rem sleep period increasing agent and sedative agent |
-
2014
- 2014-12-26 JP JP2015555033A patent/JPWO2015099102A1/en not_active Abandoned
- 2014-12-26 CN CN201480060928.7A patent/CN105705144A/en active Pending
- 2014-12-26 WO PCT/JP2014/084448 patent/WO2015099102A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009261361A (en) * | 2008-04-28 | 2009-11-12 | Sanei Gen Ffi Inc | Thick liquid food containing vegetable protein |
| JP2012036112A (en) * | 2010-08-05 | 2012-02-23 | Sankyo:Kk | Method for manufacturing product for improving bioavailability, and the product |
Non-Patent Citations (3)
| Title |
|---|
| CHARLES COUDRAY ET AL.: "Dietary Inulin Intake and Age Can Affect Intestinal Absorption of Zinc and Copper in Rats", 《JOURNAL OF NUTRITION》 * |
| MARIANGELA RONDANELLI ET AL.: "The Effect of Melatonin, Magnesium, and Zinc on Primary Insomnia in Long-Term Care Facility Residents in Italy: A Double-Blind, Placebo-Controlled Clinical Trial", 《JOURNAL OF THE AMERICAN GERIATRICS SOCIETY》 * |
| SHOKO MIYAZATO ET AL.: "Promotive effects of resistant maltodextrin on apparent absorption of calcium, magnesium, iron and zinc in rats", 《EUR J NUTR》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI760507B (en) * | 2017-06-14 | 2022-04-11 | 日商朝日飲料股份有限公司 | Non-carbonated liquid food and drink containing microbial cells, and method for improving the dispersibility of sediment or aggregate of microbial cell powder in food and drink |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2015099102A1 (en) | 2017-03-23 |
| WO2015099102A1 (en) | 2015-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102242070B (en) | Method for artificially culturing paecilomyces cicadae and application of culturing product thereof | |
| US20060134197A1 (en) | Method of reducing unpleasant taste and/or unpleasant odor | |
| CN101925361A (en) | Plant-origin drug for preventing or improving hyperuricemia | |
| CN107105742B (en) | Composition for preventing or improving non-alcoholic fatty liver disease comprising white lablab seed extract as active ingredient | |
| CN107927479A (en) | A kind of fruity sleeping water and preparation method thereof | |
| CN102665725A (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| JP5869882B2 (en) | Insulin resistance prevention and / or improvement agent | |
| US6815433B2 (en) | Composition and method for the treatment of dysglucaemia | |
| CN101300000A (en) | Equol level regulator | |
| CN104684583A (en) | Sleep-improving agent, non-REM sleep time-increasing agent, and sedative agent | |
| CN102481303B (en) | Glucose metabolism-improving agent and glucose metabolism-improving composition | |
| CN105705144A (en) | Zinc-containing sleep-improving agent, non-rem sleep time-increasing agent, and sedative | |
| KR20180037597A (en) | Composition for modifying a clock gene expression | |
| CN100496536C (en) | Alpha-glucosidase activity inhibitor | |
| CN109700028A (en) | Postprandial blood sugar suitable for I crowd of visible peristalsis visible intestinal peristalsis adjusts the dietary composition with prevention | |
| CN102470142A (en) | Composition containing chitooligosaccharide for recovering from fatigue | |
| CN102987501A (en) | Method for preparing nutrient (liquid) beverages and granules of healthcare food (therapy) products by using extractives of cordyceps militaris and cocoons | |
| JP3681193B2 (en) | α-Isomaltosyl α-isomaltoside, production method thereof and use | |
| JP2004323469A (en) | Medicinal composition and food for prevention and treatment of type ii diabetes | |
| JP2007091630A (en) | Food composition and oral skin ameliorating agent | |
| CN108185251A (en) | A kind of Rohan ginseng cloudy juice and preparation method thereof | |
| CN110279051A (en) | A kind of pectase beverage and preparation method thereof improving sleep | |
| JP6261798B1 (en) | Food composition | |
| JP6154029B2 (en) | Sleep improving agent, non-REM sleep time increasing agent and sedative | |
| KR20190066460A (en) | Pharmaceutical composition comprising the seed extracts of rambutan as an effective component for prevention or treatment of diabetes and health functional food comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160622 |
|
| WD01 | Invention patent application deemed withdrawn after publication |